NewsBenzingaReported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate Benzinga 2026.11.06 06:01 (GMT+0) Open on Benzinga Other news BTIG Reiterates Buy on US Foods Holdings, Maintains $120 Price Target Baird Downgrades Helios Technologies to Neutral, Lowers Price Target to $65 Stock Market Today: Dow Jones, S&P 500 Futures Trade Mixed Ahead of October's Jobs Report— Airbnb, Cloudflare, Lam Research in Focus Market News: US Democrats to Target Apple, Meta and Musk's Companies in Investigations QCP Capital on Democrats Taking Both Chambers: Democrats Fall Short of Two-Thirds Majority, Cannot Override Trump's Veto PBOC Responds to Shutdown of Solana's Shanghai Offline Event: Entities and Individuals Involved Will Be Investigated
Stock Market Today: Dow Jones, S&P 500 Futures Trade Mixed Ahead of October's Jobs Report— Airbnb, Cloudflare, Lam Research in Focus
QCP Capital on Democrats Taking Both Chambers: Democrats Fall Short of Two-Thirds Majority, Cannot Override Trump's Veto
PBOC Responds to Shutdown of Solana's Shanghai Offline Event: Entities and Individuals Involved Will Be Investigated
